Abstract
The role of biomarker assessment in determining the best therapeutic options for patients with metastatic colorectal cancer has become increasingly complex and important. Biomarkers that predict the efficacy and/or toxicity of such treatments can affect medical decision making, leading to decreased harm and/or costs associated with treatment and improvements in therapeutic outcomes for patients. This review discusses traditional and emerging biomarkers of potential clinical utility for patients with metastatic colorectal cancer, current assays and methods used in clinical practice, technologies that have allowed the identification of new biomarkers and key considerations for oncologists and pathologists when determining appropriate biomarker evaluations to be undertaken for their patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1033-1048 |
| Number of pages | 16 |
| Journal | Expert Review of Molecular Diagnostics |
| Volume | 15 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1 Nov 2015 |
Keywords
- BRAF mutation
- cetuximab
- colorectal cancer
- panitumumab
- predictive biomarker
- prognostic biomarker
- RAS mutation
